Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Securities

Provectus Biopharmaceuticals CEO, Edward Pershing, acquired convertible promissory notes and preferred stock, potentially increasing his stake in the company.

Summary

• Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note for $100,000 on January 30, 2025.
• This note can be converted into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note will automatically convert into preferred stock on January 30, 2026, if not converted earlier.
• Pershing also acquired 34,941 shares of Series D-1 Convertible Preferred Stock, which are convertible into common stock.
• Each share of Series D-1 Preferred Stock can be converted into 10 shares of common stock.
• The preferred stock will automatically convert into common stock on June 26, 2026, unless converted earlier.

Sentiment

Score: 7

Explanation: The document indicates a positive sign of management's commitment through investment, but also introduces potential dilution risks. The sentiment is moderately positive.

Positives

• The CEO's investment demonstrates confidence in the company's future.
• The conversion of the note and preferred stock could lead to increased equity ownership for the CEO.

Risks

• The conversion of the note and preferred stock could dilute existing shareholders if converted to common stock.
• The terms of the 2025 Financing are not fully detailed in this document.

Future Outlook

The document outlines the potential conversion of the promissory note and preferred stock into common stock, which could impact the company's capital structure.

Industry Context

This type of transaction is common in the biotech industry, where convertible securities are often used to raise capital and incentivize management.

Comparison to Industry Standards

• Convertible notes and preferred stock are frequently used by biotech companies like Provectus to secure funding, similar to companies such as Novavax and Moderna in their early stages.
• The conversion terms, such as the $2.862 conversion price and the automatic conversion dates, are typical for these types of financing agreements.
• The use of a Series D-1 preferred stock is a common mechanism for providing investors with a higher level of protection and potential upside compared to common stock.

Stakeholder Impact

• Shareholders may experience dilution if the convertible securities are converted to common stock.
• The CEO's increased stake could align his interests more closely with those of shareholders.

Next Steps

• The promissory note will either be voluntarily converted or automatically converted on January 30, 2026.
• The preferred stock will either be voluntarily converted or automatically converted on June 26, 2026.

Key Dates

Keywords

Convertible Securities, Promissory Note, Preferred Stock, Beneficial Ownership, SEC Form 4, Provectus Biopharmaceuticals, Edward Pershing